Aimei Health Technology Co., Ltd - Ordinary Share

Aimei Health Technology is a blank‑check company with no products, customers, or proprietary assets. Intangible assets: 10/100 for sponsor relationships and listing venue. Switching costs: 0/100 as there are no customers.

Network effects: 0/100. Cost advantages: 0/100. Efficient scale: 0/100. Overall moat durability is negligible until and unless a merger with a high‑quality target closes, which is uncertain following termination of the United Hydrogen agreement on July 8, 2026.

There is no operating business and no revenue. The entity cannot raise prices because it sells no goods or services. Any future economics depend entirely on an unidentified merger partner. Rights only convert if a transaction closes and are worthless upon liquidation.

Short‑term asset value is reasonably anchored by cash and T‑bills in the trust account with a disclosed per‑share redemption value of 11.80 dollars at March 31, 2026, rising modestly with monthly extension deposits and interest. Long‑term cash flows are wholly unpredictable because no operating target is in place and prior deal was terminated.

The SPAC has a finite life up to 36 months from the December 6, 2023 IPO, implying an outside date of December 6, 2026 absent a completed merger.

Balance sheet substance is the segregated trust: 12.28 million dollars as of March 31, 2026, or 11.80 dollars per redeemable share. Outside the trust, cash was minimal and the company disclosed a working capital deficit, with going‑concern language tied to the merger deadline.

Extension deposits are funded by sponsor promissory notes that are non‑interest bearing and convertible into units at 10 dollars per unit if a deal closes. While trust cash protects public shareholders at redemption, it does not fund operations prior to a merger and cannot be used except for specified purposes.

Capital is passively invested in short‑duration U.S. government securities inside the trust. Sponsor and target paid monthly extension fees in 2025 and 2026, most recently 34,330.96 dollars per month, via promissory notes that may convert into private units at 10 dollars each upon a merger.

This structure, together with 1,725,000 founder shares, 69,000 representative shares, private units, and 1/5‑share rights, creates substantial dilution upon de‑SPAC and misaligns incentives with long‑term compounding for public holders. Deferred underwriting fees of 690,000 dollars further burden a prospective transaction.

Leadership is SPAC‑oriented rather than operator‑oriented. The CEO, Junheng Xie, and CFO, Heung Ming Wong, oversee the vehicle, with the CFO holding multiple micro‑cap directorships according to the 10‑K.

Governance risk is accentuated by late filings that triggered Nasdaq deficiency notices and by China‑related disclosures indicating potential PRC regulatory processes for certain targets. There is no demonstrated track record here of acquiring and operating a high‑quality business that compounds free cash flow per share over time.